• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nemaura prices $2.5m offering to support launch of wearable glucose monitor

December 20, 2018 By Sarah Faulkner

Nemaura logoNemaura Medical (NSDQ:NMRD) said this week that it priced a public offering of the company’s common stock and warrants, hoping to reel in $2.5 million in proceeds.

The offering is slated to close today. Nemaura plans to use the offering’s proceeds to support the launch of its wearable glucose monitor in Europe, as well as the development of its second-generation system and a clinical trial in the U.S.

The company’s sugarBeat device features a disposable, adhesive patch that connects to a rechargeable transmitter. The system sends glucose readings to a mobile app at five-minute intervals for up to 24 hours.

Also this week, Nemaura published clinical data from a trial designed to support a de novo submission to the FDA for its sugarBeat device.

In the 75-person study, investigators took blood samples via a catheter every 15 minutes over a 12-hour period for 3 non-consecutive days for a total of 225 patient days. The samples were measured using an Architect c8000 laboratory instrument, Nemaura said.

More than 12,000 paired data points were analyzed using 1-point and 2-point calibration. MARD +/- 20% was 8.02% for the single finger prick calibration and 7.96% for the 2-point calibration, the company reported.

Nemaura said that the data are in line with company expectations and compare well with competitive products. The company is gearing up for a de novo application to the FDA in the first quarter of 2019.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Featured, Funding Roundup, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Nemaura Medical

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS